B+
Bull case
25%
Probability
Target price
$25.00
Analysis reference price unavailable
Analysis 2026-09-26 · RankAlpha Sentiment Codex
LEGN
Legend BiotechDNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
Current thesis
CARVYKTI's reported sales growth, positive second-quarter operating income and durable five-year clinical data could support further adoption and operating leverage. LB2501 offers longer-term optionality, but remains early-stage.
Posture
Defensive
Lead driver
Sentiment
What changed
1 setup hits (3d) with net bullish as of 2026-10-28.
What can break
CARTITUDE-2 Cohort A's five-year result covers only 20 patients; broader clinical and commercial implications remain uncertain.
Momentum
63
Value
41
Sentiment
43
Setup hits (3d)
1 · Net Bullish
AI TargetsBase $19.00 · Bull $25.00 · Bear $13.00Analysis 2026-09-26; returns require an exact persisted reference.
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-10-28 • Vendor: Data Vendor v1
Scores
As of 2026-10-28 • Model: HYBRID_IC_RP
AI Memo
As of 2026-09-26 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-10-28
Investment thesis
As of 2026-10-28
Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-10-28. Definitions
Supporting evidence
What
Grade D · Defensive
Confidence Medium · Net Bullish
Target $45.21
Why
Momentum63 · Δ7d +16.4
Value41 · Δ7d -0.1
Sentiment43 · Δ7d -12.3
So what
Weak posture (Net Bullish). Prioritize risk control and patience.
Confirming evidence
- • 1 setup hits (3d) with net bullish as of 2026-10-28.
- • Sentiment remains the lead driver in the composite, 7D delta -12.3.
Contradictions & invalidation
- • CARTITUDE-2 Cohort A's five-year result covers only 20 patients; broader clinical and commercial implications remain uncertain.
- • CARVYKTI concentration makes sales growth, access, manufacturing execution and safety disproportionately important.
- • Legend remains heavily dependent on CARVYKTI.
Catalyst clock
2026-09-25
Five-year CARVYKTI data require clinical and commercial interpretation
Lead driver: Sentiment · See AI snapshot
Momentum
63
8% active weight
Current posture
7d trendImproving
Δ7d
+16.4
Δ21d
+28.1
Value
41
47% active weight
Current posture
7d trendFlat
Δ7d
-0.1
Δ21d
-0.3
Sentiment
43
45% active weight
Current posture
7d trendSoftening
Δ7d
-12.3
Δ21d
-20.7
Why this grade
Composite grade D. Momentum 63.2 / Value 40.6 / Sentiment 43.1
Scenario snapshot
Scenario probability is memo-authored likelihood, not forecast certainty. Targets belong to the analysis dated 2026-09-26. Scenario method
Most likely
B
Base case
50%
Probability
Target price
$19.00
Analysis reference price unavailable
Analysis 2026-09-26 · RankAlpha Sentiment Codex
B-
Bear case
25%
Probability
Target price
$13.00
Analysis reference price unavailable
Analysis 2026-09-26 · RankAlpha Sentiment Codex
Fundamentals (TTM)As of 2026-10-28
Fundamentals (TTM)
As of 2026-10-28
Market Cap
$4.37B
Beta
0.11
Shares Out
193.77M
P/E (TTM) · Derived
-14.0
P/S (TTM)
4.13
P/FCF (TTM) · Derived
-15.90
Rev YoY
+51.6%
EPS YoY
-126.0%
Gross Margin
+53.0%
Op Margin
-4.1%
Net Debt
-$534.9M
Current Ratio
3.04
As of 2026-10-28 • Updated nightlySource: Internal modelMethods & Data